抗精神病药相关流涎的药物干预:随机试验的系统综述与网络荟萃分析
该系统综述与网络荟萃分析纳入34项随机对照试验(33项进入NMA,n=1958),全部针对精神障碍患者中氯氮平所致流涎。多种药物在应答率上优于安慰剂,其中甲氧氯普胺、赛庚啶、舒必利等证据较一致,但总体证据置信度低。
要点
- 甲氧氯普胺、赛庚啶、舒必利等药物在改善氯氮平相关流涎应答上优于安慰剂。
- 抗胆碱能药、苯甲酰胺类、三环类抗抑郁药和抗组胺药整体优于安慰剂。
- 证据置信度低,临床决策应结合患者偏好进行共享决策。
核心结论
- 对氯氮平所致流涎,甲氧氯普胺、赛庚啶、舒必利等药物应答率优于安慰剂,但总体证据置信度低。
研究设计与样本
- 系统检索PubMed Central、PsycInfo、Cochrane Central、Clinicaltrials.gov、WHO-ICTRP及维普数据库,纳入截至2023年6月12日的成人抗精神病药相关流涎随机对照试验。
- 34项RCT进入系统综述,33项进入网络荟萃分析(n=1958),所有干预均针对精神障碍患者的氯氮平所致流涎。
主要发现
- 在应答率上,甲氧氯普胺(RR=3.11, 95%CI 1.39-6.98)、赛庚啶(RR=2.76, 95%CI 2.00-3.82)、舒必利(RR=2.49, 95%CI 1.65-3.77)等优于安慰剂,但格隆溴铵或异丙托溴铵未显示优于安慰剂。
- 按作用机制,抗胆碱能药(RR=2.26, 95%CI 1.91-2.68)、苯甲酰胺类(RR=2.23, 95%CI 1.75-3.10)、三环类抗抑郁药(RR=2.23, 95%CI 1.83-2.72)和抗组胺药(RR=2.18, 95%CI 1.83-2.59)优于安慰剂。
- 在头对头比较中,阿司咪唑和异丙托溴铵被多种干预超越;除苯甲酰胺类外,所有二级节点在连续疗效结局上优于安慰剂。
- 针对夜间流涎,苯甲酰胺类和阿托品均未优于安慰剂;活性干预与安慰剂在便秘或嗜睡/困倦方面无显著差异。
关键数值与推荐
- 主要疗效结局为唾液分泌变化(SMD)和研究定义的应答(RR);可接受性结局为全因停药(RR)。
- 主要节点为药物分子,作用机制为次要节点;采用亚组和敏感性分析,并评估整体/局部不一致性、发表偏倚、偏倚风险(RoB2)及证据置信度。
临床怎么用
- 基于主要节点的共同主要疗效结局和头对头比较,流涎疗效最一致的药物依次为甲氧氯普胺、赛庚啶、舒必利、丙胺太林、苯海拉明、苯海索、多塞平、氨磺必利、氯苯那敏、阿米替林和阿托品(后者不用于夜间流涎)。
- 针对氯氮平相关流涎的治疗决策应与患者进行共享决策。
局限性
- 证据置信度低,结果解释需谨慎。
- 所有干预均针对氯氮平所致流涎,结论外推至其他抗精神病药需谨慎。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Antipsychotic-induced sialorrhea carries a significant burden, but evidence-based treatment guidance is incomplete, warranting network meta-analysis (NMA) of pharmacological interventions for antipsychotic-related sialorrhea. PubMed Central/PsycInfo/Cochrane Central database/Clinicaltrials.gov/WHO-ICTRP and the Chinese Electronic Journal Database (Qikan.cqvip.com) were searched for published/unpublished RCTs of antipsychotic-induced sialorrhea (any definition) in adults, up to 06/12/2023. We assessed global/local inconsistencies, publication bias, risk of bias (RoB2), and confidence in the evidence, conducting subgroup/sensitivity analyses. Co-primary efficacy outcomes were changes in saliva production (standardized mean difference/SMD) and study-defined response (risk ratios/RRs). The acceptability outcome was all-cause discontinuation (RR). Primary nodes were molecules; the mechanism of action (MoA) was secondary. Thirty-four RCTs entered a systematic review, 33 NMA (n = 1958). All interventions were for clozapine-induced sialorrhea in subjects with mental disorders. Regarding individual agents and response, metoclopramide (RR = 3.11, 95% C.I. = 1.39-6.98), cyproheptadine, (RR = 2.76, 95% C.I. = 2.00-3.82), sulpiride (RR = 2.49, 95% C.I. = 1.65-3.77), propantheline (RR = 2.39, 95% C.I. = 1.97-2.90), diphenhydramine (RR = 2.32, 95% C.I. = 1.88-2.86), benzhexol (RR = 2.32, 95% C.I. = 1.59-3.38), doxepin (RR = 2.30, 95% C.I. = 1.85-2.88), amisulpride (RR = 2.23, 95% C.I. = 1.30-3.81), chlorpheniramine (RR = 2.20, 95% C.I. = 1.67-2.89), amitriptyline (RR = 2.09, 95% C.I. = 1.34-3.26), atropine, (RR = 2.03, 95% C.I. = 1.22-3.38), and astemizole, (RR = 1.70, 95% C.I. = 1.28-2.26) outperformed placebo, but not glycopyrrolate or ipratropium. Across secondary nodes (k = 28, n = 1821), antimuscarinics (RR = 2.26, 95% C.I. = 1.91-2.68), benzamides (RR = 2.23, 95% C.I. = 1.75-3.10), TCAs (RR = 2.23, 95% C.I. = 1.83-2.72), and antihistamines (RR = 2.18, 95% C.I. = 1.83-2.59) outperformed placebo. In head-to-head comparisons, astemizole and ipratropium were outperformed by several interventions. All secondary nodes, except benzamides, outperformed the placebo on the continuous efficacy outcome. For nocturnal sialorrhea, neither benzamides nor atropine outperformed the placebo. Active interventions did not differ significantly from placebo regarding constipation or sleepiness/drowsiness. Low-confidence findings prompt caution in the interpretation of the results. Considering primary nodes' co-primary efficacy outcomes and head-to-head comparisons, efficacy for sialorrhea is most consistent for the following agents, decreasing from metoclopramide through cyproheptadine, sulpiride, propantheline, diphenhydramine, benzhexol, doxepin, amisulpride, chlorpheniramine, to amitriptyline, and atropine (the latter not for nocturnal sialorrhea). Shared decision-making with the patient should guide treatment decisions regarding clozapine-related sialorrhea.
引用
- Fornaro M, Caiazza C, Solini N, et al. Pharmacological interventions for antipsychotic-related sialorrhea: a systematic review and network meta-analysis of randomized trials. Mol Psychiatry. 2023. PMID: 37821573. doi:10.1038/s41380-023-02266-x
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。